Thalassaemia International Federation (TIF)’s Post

A Phase 2 #clinicaltrial has revealed that a #bonemarrowtransplant (BMT) approach, which sidesteps the use of high-dose chemotherapy, significantly enhances event-free and overall #survival rates in #patients with #sicklecell disease (#SCD). This cutting-edge method employs a non-myeloablative conditioning regimen prior to transplantation. This prepares the body to accept new cells by preserving some existing #StemCells, thereby lowering the likelihood of #donorcellrejection—a significant concern for adult recipients. Two years post-transplantation, the event-free survival rate was approximately 83%, while the overall survival rate stood at an impressive 94%, as per the reports from the #researchers. Read more 👇 https://lnkd.in/d-Yy3cBj

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics